* Magenta Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on August 2 (estimated).
*
* Refinitiv's mean analyst estimate for Magenta Therapeutics Inc is for a loss of 19 cents per share.
* The one available analyst rating on the shares is "hold".
* The mean earnings estimate of analysts had fallen by about 24.2% in the last three months.
* Wall Street's median 12-month price target for Magenta Therapeutics Inc is $1, above its last closing price of $0.81.
This summary was machine generated July 31 at 16:00 GMT. All figures in US dollars unless otherwise stated.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。